In a randomized double-blind cross-over trial we gave either 1-deamino-8-D-arginine vasopressin or placebo to 12 patients with uremia, hemorrhagic tendencies, and prolonged bleeding times. After vasopressin infusion, all patients had shortened bleeding times, with the effect lasting for at least four hours in most cases. Platelet count, platelet cyclic AMP levels, platelet retention on glass beads, plasma fibronectin, serum thromboxane B2 and residual prothrombin, hematocrit, and plasma osmolarity were unchanged after vasopressin. A consistent post-infusion increase in factor VIII coagulant activity and, to a lesser extent, in factor VIII-related antigen and ristocetin cofactor accompanied the shortening of bleeding time. In addition, vasopressin induced the appearance in plasma of larger von Willebrand-factor multimers than those present in the resting state. The compound was given to nine additional patients with acute or chronic renal failure and prolonged bleeding times, before major surgery or renal biopsy. In these patients, shortening of the bleeding time was associated with normal hemostasis. Our findings indicate that 1-deamino-8-D-arginine vasopressin can be used for temporary correction of bleeding time and may prevent surgical bleeding in patients with uremia.
This article has been cited by other articles:
Liu, C-H, Liang, C-C, Lin, J-W, Chen, S-I, Tsai, H-B, Chang, C-S, Hung, P-H, Kao, J-H, Liu, C-J, Lai, M-Y, Chen, J-H, Chen, P-J, Kao, J-H, Chen, D-S
(2008). Pegylated interferon {alpha}-2a versus standard interferon {alpha}-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut
57: 525-530
[Abstract][Full Text]
Mannucci, P. M., Levi, M.
(2007). Prevention and Treatment of Major Blood Loss. NEJM
356: 2301-2311
[Full Text]
KUO, M.-C., CHANG, J.-M., LU, P.-L., CHIU, Y.-W., CHEN, H.-C., HWANG, S.-J.
(2007). DIFFICULTY IN DIAGNOSIS AND TREATMENT OF DENGUE HEMORRHAGIC FEVER IN PATIENTS WITH CHRONIC RENAL FAILURE: REPORT OF THREE CASES OF MORTALITY. Am J Trop Med Hyg
76: 752-756
[Abstract][Full Text]
Chinsky, K.
(2005). Bleeding Risk and Bronchoscopy: In Search of the Evidence in Evidence-Based Medicine. Chest
127: 1875-1877
[Full Text]
Fehr, T., Ambuhl, P. M.
(2004). Chronic hepatitis virus infections in patients on renal replacement therapy. Nephrol Dial Transplant
19: 1049-1053
[Full Text]
Koscielny, J., von Tempelhoff, G.-F., Ziemer, S., Radtke, H., Schmutzler, M., Sinha, P., Salama, A., Kiesewetter, H., Latza, R.
(2004). A Practical Concept for Preoperative Management of Patients With Impaired Primary Hemostasis. CLIN APPL THROMB HEMOST
10: 155-166
[Abstract]
Lehman, C. M., Blaylock, R. C., Alexander, D. P., Rodgers, G. M.
(2001). Discontinuation of the Bleeding Time Test without Detectable Adverse Clinical Impact. Clin. Chem.
47: 1204-1211
[Abstract][Full Text]
Mazzuchi, N., Gonzalez-Martinez, F., Carbonell, E., Curi, L., Fernandez-Cean, J., Orihuela, S.
(1999). Comparison of survival for haemodialysis patients vs renal transplant recipients treated in Uruguay. Nephrol Dial Transplant
14: 2849-2854
[Abstract][Full Text]
Ifudu, O.
(1998). Care of Patients Undergoing Hemodialysis. NEJM
339: 1054-1062
[Full Text]
Mannucci, P. M.
(1998). Hemostatic Drugs. NEJM
339: 245-253
[Full Text]
Peterson, P., Hayes, T. E., Arkin, C. F., Bovill, E. G., Fairweather, R. B., Rock, W. A. Jr, Triplett, D. A., Brandt, J. T.
(1998). The Preoperative Bleeding Time Test Lacks Clinical Benefit: College of American Pathologists' and American Society of Clinical Pathologists' Position Article. Arch Surg
133: 134-139
[Abstract][Full Text]
Mannucci, P. M.
(1997). Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years. Blood
90: 2515-2521
[Full Text]
Despotis, G. J., Joist, J. H., Goodnough, L. T.
(1997). Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes. Clin. Chem.
43: 1684-1696
[Abstract][Full Text]
Moulton, M. J., Creswell, L. L., Mackey, M. E., Cox, J. L., Rosenbloom, M.
(1996). REEXPLORATION FOR BLEEDING IS A RISK FACTOR FOR ADVERSE OUTCOMES AFTER CARDIAC OPERATIONS. J. Thorac. Cardiovasc. Surg.
111: 1037-1046
[Abstract][Full Text]
Lethagen, S.
(1993). Desmopressin (DDAVP), tranexamic acid and haemostasis. Perfusion
8: 417-425
[Abstract]
Spyt, T., Weerasena, N., Bain, W., Lowe, G., Rumley, A.
(1990). The effects of desmopressin acetate (DDAVP) on haemostasis and blood loss in routine coronary artery bypass surgery: a randomized, double-blind trial I. Perfusion
5: 57-61
[Abstract]
Kickler, T.
(1989). How Safe Are Transfusions? Measures to Increase Safety. J Intensive Care Med
4: 93-94
Bidstrup, B. P
(1988). Review article : Blood conservation in cardiac surgery: can drugs help?. Perfusion
3: 171-177
Previous
